

Assess Risk for Ovarian Cancer in Pelvic Masses

with Testing from ASPIRA Labs



For women with adnexal mass, **OVA1®plus** is a reflex process which first performs OVA1 and then performs OVERA® if the OVA1 result is in the intermediate range.

Superior Detection for Risk of Ovarian Cancer with OVA1plus

"Because CA 125 often is negative when early stage cancer is present, or positive when cancer is not, it is not recommended for preoperative use for determining whether an ovarian tumor is malignant or whether surgery is indicated.¹"

Comparison of Serum Biomarker Performance¹

Sensitivity	Overa	OVA1	ROMA	CA 125
All malignancies	91%	93%	89%	69%
Epithelial ovarian cancers (EOC)	95%	99%	94%	82%
Early stage EOC	89%	98%	75%	66%

1. Ueland, Frederick R. and Fredericks, Tricia I. ; Ovarian masses: Surgery or surveillance? OBG Management. June 2018. Vol. 30 No. 6

OVA1[®] is sensitive for **detecting risk for** all subtypes of Epithelial ovarian cancer

including mucinous type tumors.

Additional Biomarkers for Epithelial Mucinous Type Tumors

🚾 CA19-9 🛛 🔤 CEA

DID YOU KNOW? CA125 and HE4 are **not sensitive** to detect mucinous type tumors.

s.

Epithelial Ovarian Cancer Makes Up the Majority of Ovarian Cancer Tumor Types

Ovarian Cancer Tumor Type	Epithelial	Germ-cell	Stromal-cell	Other (Metastases)
Frequency (approximate)	75%	15%	5%	5%
Age group	20+ Years	<35 years	All Ages	Variable



Germ-cell Tumor Ovarian Cancer Risk Biomarkers

- NEW AFP

βHCG

WHEN TO CONSIDER THESE BIOMARKERS?

Germ-Cell tumors are suspected in women <35 years of age but may occur at any age.

p: 844.277.4721 | e: aspirasupport@aspirawh.com

© 2020 ASPIRA Women's Health. All rights reserved. The ASPIRA LABS®, OVA1® and OVERA® logos are registered trademarks of ASPIRA Women's Health in the U.S. and other countries. ASPIRA Women's Health reserves the right to change this document at any time without notice and disclaims liability for editorial, pictorial or typographical errors.

